EPM
EFTRW

Equitec Proprietary Markets’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Equitec Proprietary Markets’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-37,700
Closed -$8K – 287
2022
Q2 		$8K Hold
37,700
– – ﹤0.01% 191
2022
Q1 		$13K Hold
37,700
– – ﹤0.01% 166
2021
Q4 		$33K Buy
37,700
+25,000
+197% +$31.4K ﹤0.01% 255
2021
Q3 		$20K Buy
+12,700
New +$15.4K ﹤0.01% 178

Other funds holding EFTRW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ECM
Evolution Capital Management Crystal Bay, Nevada $29M AUM 2.56% 1-Year Est. Return
ICM
III Capital Management Boca Raton, Florida $344M AUM 11.22% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Equitec Proprietary Markets's EFTRW Position: Q3 2022 in Review

Equitec Proprietary Markets sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2022, closing a stake of 37,700 shares — an estimated $8K sold.

Equitec Proprietary Markets first reported a position in EFTRW in Q3 2021 and held it in 4 quarters. The position peaked at $33K in Q4 2021. 12 funds tracked by Wall St. Rank hold EFTRW as of Q3 2022.

  • Equitec Proprietary Markets reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2022 after selling out during the quarter.
  • Equitec Proprietary Markets sold 37,700 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2022, an estimated $8K.
  • Equitec Proprietary Markets first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q3 2021 and held it in 4 quarters.
  • Equitec Proprietary Markets's eFFECTOR Therapeutics, Inc. Warrant position peaked at $33K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2022.

Based on Equitec Proprietary Markets's 13F filing for Q3 2022, filed 11 Oct 2022.